Cipla, Jubilant Life, Hetero, Mylan ink licensing pact with Gilead for COVID-19 drug remdesivir
New Delhi: Four domestic pharma firms – Cipla, Jubilant Life Sciences, Hetero and Mylan – have entered into non-exclusive licensing agreements...
New Delhi: Four domestic pharma firms – Cipla, Jubilant Life Sciences, Hetero and Mylan – have entered into non-exclusive licensing agreements...
New Delhi: The Supreme Court Wednesday declined to entertain an interim bail plea filed on medical grounds by former senior...
New Delhi: As coronavirus pandemic and the nationwide lockdown have brought a near standstill to economic activities, a TRA survey...
New Delhi: A Railway Protection Force (RPF) personnel, who visited the railway ministry office a week ago, has tested positive...
Sydney: A global team led University of New South Wales (UNSW), Sydney aims to track the long-term impacts of COVID-19...
Hyderabad: Southern superstar Samantha Akkineni is in no mood to skip staying fit amid the lockdown, going by a string...
New Delhi: Legendary India batsman Sachin Tendulkar has once again said that the current ODI rules need to be looked...
New Delhi: Host and actor Maniesh Paul, who has made a short film titled "What If", a thriller, revolving around...
New Delhi: There are enough indications that restrictions on mass transport systems will be removed during lockdown 4.0. This was...
Sydney: Former India coach Greg Chappell said that MS Dhoni is the most powerful batsman he has ever seen. Chappell...
It is the fifth week running since US President Donald Trump and Israeli Prime Minister Benjamin Netanyahu launched the war...
Read moreDetailsWhile a big war is being waged in the Middle East, global attention has moved away from another theatre of...
Read moreDetailsFuel has been a long-time great economic and political tool in the hands of the government in India. It enables...
Read moreDetailsConsider this thought experiment. Imagine that two large missiles struck the White House. The first hit the residential quarters at...
Read moreDetails